跳至主要内容
临床试验/NCT05148598
NCT05148598尚未招募3 期

Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells - A Randomized, Double-Blind, Placebo-Controlled Study - The STAR-II Trial

Paracrine, INC.0 个研究点目标入组 174 人开始时间: 2023年2月28日最近更新:
适应症

试验速览

阶段
3 期
状态
尚未招募
入组人数
174
主要终点
Cochin Hand Function Score

研究概览

简要总结

The primary objective of this study is to assess the safety and efficacy of the Celution Device in the processing of an autologous graft consisting of adipose derived regenerative cells (ADRCs) in the treatment of hand dysfunction due to scleroderma.

详细描述

The primary objective of this study is to assess the safety and efficacy of the Celution Device in the processing of an autologous graft consisting of adipose derived regenerative cells (ADRCs) in the treatment of hand dysfunction due to scleroderma.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

盲法说明

Placebo is visually indistinguishable from active treatment.

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diffuse cutaneous scleroderma (duration > 5 years)
  • Cochin Hand Function Scale ≥ 20 units
  • Symptoms consistent with Raynaud's Phenomenon
  • Ability to safely undergo liposuction

排除标准

  • Active infection
  • Contracture(s) of any finger
  • Sympathectomy within 6 months of Screening Visit
  • Rheumatoid Arthritis

结局指标

主要结局

Cochin Hand Function Score

时间窗: 26 weeks

Cochin Hand Function Score

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

相似试验